AllPennyStocks.com Lilly’s revenue soars 48%, driven by demand of its GLP-1s
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Strategic Gold Asset Sale Sends Junior Miner Sharply Higher
A $14.5 Million Exit Completes a Two-Year Retreat
Most Popular
{{ index + 1 }}


Back to Top